Premium
Combined Effects of a Metabolic Inhibitor (Gabaculine) and an Uptake Inhibitor (Ketamine) on the γ‐Aminobutyrate System in Mouse Brain
Author(s) -
Wood J. D.,
Geddes J. W.,
Tsui S.K.,
Kurylo E.
Publication year - 1982
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.1982.tb08007.x
Subject(s) - pharmacology , glutamate receptor , chemistry , ketamine , gaba transaminase , glutamine , anticonvulsant , non competitive inhibition , nmda receptor , biochemistry , enzyme , biology , neuroscience , glutamate decarboxylase , amino acid , epilepsy , receptor
The intramuscular administration of a γ‐aminobutyrate‐α‐oxoglutarate aminotransferase (GABA‐T) inhibitor, gabaculine, to mice resulted in significant increases in GABA content and decreases in the content of aspartate, glutamate, and glutamine in the nerve endings (synaptosomes). These effects were ameliorated by the concurrent administration of the GABA uptake inhibitor ketamine. A major cause of these effects was the gabaculine‐induced inhibition of GABA‐T activity and the lessening of this inhibition by ketamine. The latter phenomenon was not due to a direct action of ketamine on the enzyme, nor to an interaction between gabaculine and ketamine. Rather, it appeared that ketamine might be interfering with the transport of gabaculine into the cellular structures. The anticonvulsant action of the GABA‐T inhibitor and the GABA uptake inhibitor together was little different from that of the GABA‐T inhibitor alone.